Zai Lab Limited — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter filing; the supplied filing text does not provide a clear Q4-only financial breakdown. Amounts are in U.S. dollars unless noted.
Business context
Zai Lab is a Cayman Islands holding company with substantial operations in Greater China and the United States. It focuses on developing and commercializing medicines in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its four commercial products are ZEJULA, Optune, QINLOCK, and NUZYRA; it reported 22 product candidates in development, including 13 late-stage programs as of year-end.
Financial performance and liquidity
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Total revenue | $215.0 million | $144.3 million | +49% |
| Net product revenue | $212.7 million | $144.1 million | +48% |
| Cost of sales | $74.0 million | $52.2 million | +42% |
| Gross profit / gross margin | $138.7 million / approximately 65% | $91.9 million / approximately 64% | Margin improved about 1 percentage point |
| Research and development expense | $286.4 million | $573.3 million | −50% |
| Selling, general and administrative expense | $259.0 million | $218.8 million | +18% |
| Loss from operations | $404.4 million | $700.1 million | Loss narrowed 42% |
| Net loss | $443.3 million | $704.5 million | Loss narrowed 37% |
| Operating cash flow | $(367.6) million | $(549.2) million | Cash use declined |
- ZEJULA generated $145.2 million of FY2022 net revenue (+55%); Optune $47.3 million (+22%); QINLOCK $15.0 million (+29%); and NUZYRA $5.2 million, compared with $0.003 million in 2021.
- Cash and cash equivalents were $1,008.5 million at year-end, with $0.8 million of restricted cash. Short-term investments fell from $445.0 million to nil; total cash, restricted cash, and short-term investments were $1,009.3 million, versus $1,409.9 million in 2021.
- Total liabilities were $174.5 million, mainly accounts payable, accrued liabilities, deferred income, and operating lease liabilities. The filing’s balance sheet does not show borrowings or other financial debt at year-end.
- Investing activities provided $420.0 million, mainly reflecting net maturities of time deposits; financing activities used $1.7 million, versus $820.2 million provided in 2021, when the company raised public-offering proceeds.
Material changes and unusual items
- Revenue growth reflected higher product sales and lower rebates. Gross product revenue rose 23%, while rebates and returns declined to $21.3 million from $46.1 million.
- R&D expense fell by $286.9 million, primarily because license fees declined to $53.4 million from $384.1 million. This was partly offset by higher personnel and clinical-trial costs. The reduction is therefore substantially tied to licensing-payment timing, not simply lower underlying development activity.
- SG&A rose with commercial and administrative headcount and professional services. The company reported $61.3 million of share-based compensation expense, up from $40.7 million.
- A $56.4 million foreign-currency loss in 2022, primarily from U.S.-dollar appreciation against the RMB, contrasted with a $4.7 million gain in 2021. This offset part of the improvement in operating loss.
- The 2022 statements received an unqualified audit opinion from KPMG. KPMG identified accrued preclinical and clinical trial expenses as a critical audit matter; management and the auditor reported effective internal control over financial reporting.
Outlook, commentary, and risks
- Management expects 2023 sales of the four commercial products to increase, citing ZEJULA’s hospital-market growth, new NRDL listings for QINLOCK and NUZYRA, and expanded supplemental insurance access for Optune. The filing gives no numerical revenue or loss guidance.
- The company targets overall corporate profitability by the end of 2025 and plans preparations to launch eight additional products in Greater China over the next two to three years. These are management goals, not assurances.
- Management says year-end liquidity was expected to fund operating expenses and capital expenditures for at least 12 months from the filing’s planning date, while noting additional funding may ultimately be needed. Cash used in operations remained substantial.
- Potential additional development, regulatory, and sales milestones under licensing agreements totaled up to approximately $5.3 billion, plus royalties. These amounts are contingent and are not recorded as current liabilities because achievement and timing are uncertain.
- Notable pipeline developments included positive pivotal LUNAR results for Tumor Treating Fields in NSCLC; China’s acceptance of the SUL-DUR NDA for priority review; and progress in efgartigimod, repotrectinib, adagrasib, and KarXT programs. Clinical and regulatory outcomes remain uncertain.
- Key risks include China-related regulatory and data-transfer requirements, cross-border political and trade tensions, currency controls and foreign-exchange volatility, reimbursement and pricing pressure, dependence on licensors and third-party manufacturers, clinical-trial and approval risk, and continued operating losses. COVID-related disruption had affected patient access, sales activity, supply, and trials.
- The CSRC’s overseas-offering filing rules were scheduled to take effect March 31, 2023. The company said it might need to file with the CSRC after future overseas offerings. The PCAOB had vacated its China inspection restriction in December 2022, and the company had engaged U.S.-based auditor KPMG for FY2022.
Investor verification priorities
- Check whether 2023 product growth, NRDL access, and reimbursement translate into sustained net revenue and improved margins, particularly after price reductions.
- Reconcile the sharp R&D expense decline with licensing-fee timing, active trial spending, and future milestone obligations.
- Track operating cash burn, cash and investment balances, and the timing and terms of any further financing.
- Monitor clinical readouts, regulatory decisions, and commercialization plans for late-stage programs, alongside potential supply or partner disruptions.
- Assess exposure to China data-transfer, CSRC filing, currency-conversion, and U.S. listing requirements as rules and enforcement evolve.